Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Shi'ao Tong"'
Publikováno v:
Cancer Medicine, Vol 10, Iss 22, Pp 8100-8113 (2021)
Abstract Objective To explore the role and possible regulatory mechanisms of CYP2E1 in gliomas. Methods RNA‑seq data and corresponding clinical information of glioma patients were collected from The Cancer Genome Atlas and Chinese Glioma Genome Atl
Externí odkaz:
https://doaj.org/article/2a59936b77e14d3ea75c21db495b1d2d
Autor:
Liguo Ye, Long Wang, Ji’an Yang, Ping Hu, Chunyu Zhang, Shi’ao Tong, Zhennan Liu, Daofeng Tian
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-13 (2021)
Abstract Background As an important part of tumor immunotherapy for adjunct, therapeutic tumor vaccines have been effective against multiple solid cancers, while their efficacy against lower grade glioma (LGG) remains undefined. Immunophenotyping of
Externí odkaz:
https://doaj.org/article/068ddba0e97d45e99c6ed7ea88ac1945
Autor:
Liguo Ye, Long Wang, Ji’an Yang, Ping Hu, Chunyu Zhang, Shi’ao Tong, Zhennan Liu, Daofeng Tian
Publikováno v:
Frontiers in Genetics, Vol 12 (2021)
Background: Clinical benefits from standard therapies against glioblastoma (GBM) are limited in part due to the intrinsic radio- and chemo-resistance. As an essential part of tumor immunotherapy for adjunct, therapeutic tumor vaccines have been effec
Externí odkaz:
https://doaj.org/article/8d27ffd2ca3e44688aa5448210536e1e
Publikováno v:
Journal of Cancer Research and Clinical Oncology.
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 22, Pp 8100-8113 (2021)
Cancer Medicine, Vol 10, Iss 22, Pp 8100-8113 (2021)
Objective To explore the role and possible regulatory mechanisms of CYP2E1 in gliomas. Methods RNA‑seq data and corresponding clinical information of glioma patients were collected from The Cancer Genome Atlas and Chinese Glioma Genome Atlas, and m
Autor:
Lun Gao, Junhui Liu, Shenqi Zhang, Yong Li, Yinqiu Tan, Ji’an Yang, Jiayang Cai, Long Wang, Zhang Ye, Shi’ao Tong, Gang Deng, Qiang Cai, qianxue chen
Glioblastoma (GBM, WHO grade IV) is well known for its highly metastatic and recurrent and accounts for approximately 50% of all gliomas. Dysregulation of epithelial–mesenchymal transition (EMT) can lead to malignant progression of GBM. Therefore,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a206b2fa5e3a1b6ee463f9d32d157e69
https://doi.org/10.21203/rs.3.rs-1403508/v3
https://doi.org/10.21203/rs.3.rs-1403508/v3
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
Aberrant reprogramming of metabolism has been considered a hallmark in various malignant tumors. The metabolic changes of amino acid not only have dramatic effects in cancer cells but also influence their immune-microenvironment in gliomas. However,
Autor:
Xiaobin Li, Lirui Guo, Qianxue Chen, Liguo Ye, Yinqiu Tan, Shi’ao Tong, Haitao Liu, Chunyu Zhang, Zhongzhou Su, Daofeng Tian, Na Luo, Pengfei Xu
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Frontiers in Cell and Developmental Biology
Frontiers in Cell and Developmental Biology
The tumor immune microenvironment (TIME) has been recognized to be associated with sensitivity to immunotherapy and patient prognosis. Recent research demonstrates that assessing the TIME patterns on large-scale samples will expand insights into TIME
Autor:
Jian Yang, Long Wang, Chunyu Zhang, Shi’ao Tong, Daofeng Tian, Ping Hu, Liguo Ye, Zhennan Liu
Publikováno v:
Frontiers in Genetics
Frontiers in Genetics, Vol 12 (2021)
Frontiers in Genetics, Vol 12 (2021)
Background: Clinical benefits from standard therapies against glioblastoma (GBM) are limited in part due to the intrinsic radio- and chemo-resistance. As an essential part of tumor immunotherapy for adjunct, therapeutic tumor vaccines have been effec